What question did this study set out to answer?

This study aims to evaluate the clinical outcomes of children and young adults with inflammatory bowel disease who switched to an adalimumab biosimilar due to insurance reasons.

July 8, 2026JPGN ReportsOpen Access

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

View Full Paper

Ask AI

Bookmark

This study aims to evaluate the clinical outcomes of children and young adults with inflammatory bowel disease who switched to an adalimumab biosimilar due to insurance reasons.
Retrospective chart review at a single center among patients with IBD who switched to a biosimilar.
Collected demographics, Physician Global Assessment scores, laboratory values, adalimumab levels, and antibodies pre and up to 6 months postswitch.
Statistical analyses included McNemar's exact test, linear mixed effect models, and paired t-tests to compare preswitch and postswitch variables.
86% (36/42) of patients demonstrated stable or improved Physician Global Assessment scores after switching.
76% (38/50) of patients continued on the biosimilar for at least 6 months after switching.
Adalimumab levels decreased from 18 to 15 µg/mL with a p-value of 0.007.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates clinical outcomes following nonmedical switches in children and young adults with IBD, indicating comparable effectiveness and safety.

Cite This Study

Himelstein et al. (2026) studied this question.

synapsesocial.com/papers/6a4de871d2ea289ef62832df https://doi.org/10.1002/jpr3.70212

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates clinical outcomes following nonmedical switches in children and young adults with IBD, indicating comparable effectiveness and safety.

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

Key Points

Discussion

Implication

Cite This Study

Outcomes of adalimumab biosimilar nonmedical switches in children and young adults with inflammatory bowel disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider